vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and FRANKLIN STREET PROPERTIES CORP (FSP). Click either name above to swap in a different company.
FRANKLIN STREET PROPERTIES CORP is the larger business by last-quarter revenue ($26.0M vs $18.7M, roughly 1.4× CytomX Therapeutics, Inc.). CytomX Therapeutics, Inc. runs the higher net margin — -0.8% vs -28.1%, a 27.3% gap on every dollar of revenue. On growth, FRANKLIN STREET PROPERTIES CORP posted the faster year-over-year revenue change (-8.2% vs -25.7%). FRANKLIN STREET PROPERTIES CORP produced more free cash flow last quarter ($-12.7M vs $-15.8M). Over the past eight quarters, FRANKLIN STREET PROPERTIES CORP's revenue compounded faster (-8.7% CAGR vs -15.9%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
Franklin Street Properties Corp is a Massachusetts-based real estate investment trust (REIT) in the United States. It primarily invests in, owns, and operates high-quality office properties across major U.S. metropolitan markets, serving corporate tenants across various industry segments, and delivers stable long-term returns via rental income and strategic asset management.
CTMX vs FSP — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $26.0M |
| Net Profit | $-154.0K | $-7.3M |
| Gross Margin | — | 59.4% |
| Operating Margin | -6.9% | -27.9% |
| Net Margin | -0.8% | -28.1% |
| Revenue YoY | -25.7% | -8.2% |
| Net Profit YoY | 97.6% | 14.1% |
| EPS (diluted) | — | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $26.0M | ||
| Q3 25 | — | $27.3M | ||
| Q2 25 | $18.7M | $26.7M | ||
| Q1 25 | $50.9M | $27.1M | ||
| Q4 24 | $38.1M | $28.4M | ||
| Q3 24 | $33.4M | $29.7M | ||
| Q2 24 | $25.1M | $30.8M | ||
| Q1 24 | $41.5M | $31.2M |
| Q4 25 | — | $-7.3M | ||
| Q3 25 | — | $-8.3M | ||
| Q2 25 | $-154.0K | $-7.9M | ||
| Q1 25 | $23.5M | $-21.4M | ||
| Q4 24 | $18.9M | $-8.5M | ||
| Q3 24 | $5.7M | $-15.6M | ||
| Q2 24 | $-6.5M | $-21.0M | ||
| Q1 24 | $13.8M | $-7.6M |
| Q4 25 | — | 59.4% | ||
| Q3 25 | — | 60.9% | ||
| Q2 25 | — | 59.9% | ||
| Q1 25 | — | 62.8% | ||
| Q4 24 | — | 59.7% | ||
| Q3 24 | — | 61.0% | ||
| Q2 24 | — | 64.2% | ||
| Q1 24 | — | 64.7% |
| Q4 25 | — | -27.9% | ||
| Q3 25 | — | -30.5% | ||
| Q2 25 | -6.9% | -29.2% | ||
| Q1 25 | 44.4% | -78.9% | ||
| Q4 24 | 46.4% | -29.9% | ||
| Q3 24 | 12.3% | -52.4% | ||
| Q2 24 | -33.7% | -68.0% | ||
| Q1 24 | 28.1% | -24.0% |
| Q4 25 | — | -28.1% | ||
| Q3 25 | — | -30.5% | ||
| Q2 25 | -0.8% | -29.5% | ||
| Q1 25 | 46.2% | -79.1% | ||
| Q4 24 | 49.6% | -30.0% | ||
| Q3 24 | 17.2% | -52.6% | ||
| Q2 24 | -26.0% | -68.2% | ||
| Q1 24 | 33.3% | -24.2% |
| Q4 25 | — | $-0.06 | ||
| Q3 25 | — | $-0.08 | ||
| Q2 25 | — | $-0.08 | ||
| Q1 25 | — | $-0.21 | ||
| Q4 24 | — | $-0.09 | ||
| Q3 24 | — | $-0.15 | ||
| Q2 24 | — | $-0.20 | ||
| Q1 24 | — | $-0.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $30.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $119.9M | $607.0M |
| Total Assets | $175.1M | $892.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $30.6M | ||
| Q3 25 | — | $31.4M | ||
| Q2 25 | $49.0M | $29.4M | ||
| Q1 25 | $47.6M | $30.2M | ||
| Q4 24 | $38.1M | $41.1M | ||
| Q3 24 | $40.6M | $40.9M | ||
| Q2 24 | $43.2M | $30.2M | ||
| Q1 24 | $36.2M | $34.2M |
| Q4 25 | — | $607.0M | ||
| Q3 25 | — | $615.3M | ||
| Q2 25 | $119.9M | $624.7M | ||
| Q1 25 | $25.0M | $633.4M | ||
| Q4 24 | $-456.0K | $655.9M | ||
| Q3 24 | $-23.5M | $665.4M | ||
| Q2 24 | $-31.2M | $682.1M | ||
| Q1 24 | $-31.7M | $703.9M |
| Q4 25 | — | $892.9M | ||
| Q3 25 | — | $901.0M | ||
| Q2 25 | $175.1M | $903.2M | ||
| Q1 25 | $98.5M | $916.4M | ||
| Q4 24 | $120.5M | $946.9M | ||
| Q3 24 | $139.0M | $981.5M | ||
| Q2 24 | $159.2M | $1.0B | ||
| Q1 24 | $184.7M | $1.0B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $3.8M |
| Free Cash FlowOCF − Capex | $-15.8M | $-12.7M |
| FCF MarginFCF / Revenue | -84.6% | -48.6% |
| Capex IntensityCapex / Revenue | 0.1% | 63.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | $-25.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $3.8M | ||
| Q3 25 | — | $8.3M | ||
| Q2 25 | $-15.8M | $-2.9M | ||
| Q1 25 | $-21.0M | $-5.5M | ||
| Q4 24 | $-19.9M | $9.0M | ||
| Q3 24 | $-20.7M | $14.5M | ||
| Q2 24 | $-19.5M | $-648.0K | ||
| Q1 24 | $-26.0M | $-7.1M |
| Q4 25 | — | $-12.7M | ||
| Q3 25 | — | $3.0M | ||
| Q2 25 | $-15.8M | $-5.7M | ||
| Q1 25 | $-21.2M | $-9.9M | ||
| Q4 24 | $-20.0M | $-16.2M | ||
| Q3 24 | $-20.7M | $8.6M | ||
| Q2 24 | $-19.6M | $-5.1M | ||
| Q1 24 | $-26.2M | $-15.8M |
| Q4 25 | — | -48.6% | ||
| Q3 25 | — | 11.0% | ||
| Q2 25 | -84.6% | -21.5% | ||
| Q1 25 | -41.6% | -36.7% | ||
| Q4 24 | -52.5% | -57.2% | ||
| Q3 24 | -62.1% | 29.1% | ||
| Q2 24 | -78.2% | -16.7% | ||
| Q1 24 | -63.1% | -50.8% |
| Q4 25 | — | 63.0% | ||
| Q3 25 | — | 19.4% | ||
| Q2 25 | 0.1% | 10.7% | ||
| Q1 25 | 0.2% | 16.4% | ||
| Q4 24 | 0.2% | 88.9% | ||
| Q3 24 | 0.1% | 19.6% | ||
| Q2 24 | 0.4% | 14.6% | ||
| Q1 24 | 0.3% | 28.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.89× | — | ||
| Q4 24 | -1.05× | — | ||
| Q3 24 | -3.61× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -1.89× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
FSP
Segment breakdown not available.
